| 引用本文: |
荣雪菁,娄红祥,孙强.国际药品价格政策对我国专利药品谈判采购的启示[J].中国卫生经济,2017,(1):94-96.[点击复制] |
.The Experience of International Medicine Pricing Policies and the Implication to China Patented Medicine Negotiation Policy[J].CHINESE HEALTH ECONOMICS,2017,(1):94-96.[点击复制] |
|
| 摘要: |
| 目的：借鉴国际经验，为完善我国专利药谈判采购政策提出建议。方法：关键人物访谈法和文献综述法。结果及建议：目前国际专利药定价方法主要分为基于卫生技术评估定价、外部参考定价、内部参考定价和基于成本定价等，也有的通过药品购买政策形成药品价格。我国专利药政策还需要进一步完善，专利药谈判采购政策可与我国医保政策紧密结合。外部参考定价较适合应用于目前的专利药谈判采购政策，药物经济学评价作为今后专利药品定价的发展方向。 |
| 关键词: |
| DOI： |
|
| 基金项目: |
|
| The Experience of International Medicine Pricing Policies and the Implication to China Patented Medicine Negotiation Policy |
|
| () |
| Abstract: |
| Objective: China’s new patented medicine policies could be improved with international drug pricing experience. Methods is key person interviews and literature review. Results and suggestions: Scientific pricing methods have been employed in many countries’ patented medicine pricing, which mainly include health technology assessment (HTA), external reference pricing (ERP), internal reference price, cost based pricing, as well as some purchasing policies. China’s Patented medicine policies are supposed to be related to health insurance policy. Currently, ERP could be applied to patented medicine negotiation policy, while HTA system should be established gradually. |
| Key words: |
